Molecular Biophysics and Structural Biology, University of Pittsburgh and Carnegie Mellon University, 3501 Fifth Avenue, Pittsburgh, Pennsylvania 15260, United States.
ACS Biomater Sci Eng. 2020 Jan 13;6(1):367-374. doi: 10.1021/acsbiomaterials.9b01660. Epub 2019 Dec 13.
A major obstacle for topical and enteral drug delivery is the poor transport of macromolecular drugs through the epithelium. One potential solution is the use of permeation enhancers that alter epithelial structures. Piperazine derivatives are known permeation enhancers that modulate epithelial structures, reduce transepithelial electrical resistance, and augment the absorption of macromolecular drugs. The mechanism by which piperazine derivatives disrupt the structures of epithelial monolayers is not well understood. Here, the effects of 1-phenylpiperazine and 1-methyl-4-phenylpiperazine are modeled in the epithelial cell line NRK-52E. Live-cell imaging reveals a dose-dependent gross reorganization of monolayers at high concentrations, but reorganization differs based on the piperazine molecule. Results show that low concentrations of piperazine derivatives increase myosin force generation within the cells and do not disrupt the cytoskeletal structure. Also, cytoskeletally attached cadherin junctions are disrupted before tight junctions. In summary, piperazines appear to increase myosin-mediated contraction followed by disruption of cell-cell contacts. These results provide new mechanistic insight into how transient epithelial permeation enhancers act and will inform of the development of future generations of transepithelial delivery systems.
透皮和肠内给药的主要障碍是大分子药物通过上皮的传输不良。一种潜在的解决方案是使用渗透增强剂来改变上皮结构。哌嗪衍生物是已知的渗透增强剂,可调节上皮结构,降低跨上皮电阻,并增加大分子药物的吸收。哌嗪衍生物破坏上皮单层结构的机制尚不清楚。在这里,用上皮细胞系 NRK-52E 对 1-苯哌嗪和 1-甲基-4-苯哌嗪的作用进行了建模。活细胞成像显示,在高浓度下,单层会出现剂量依赖性的整体重排,但重排因哌嗪分子而异。结果表明,哌嗪衍生物的低浓度会增加细胞内肌球蛋白的产生力,而不会破坏细胞骨架结构。此外,细胞骨架附着的钙黏着连接在紧密连接之前被破坏。总之,哌嗪似乎会增加肌球蛋白介导的收缩,然后破坏细胞-细胞接触。这些结果为瞬态上皮渗透增强剂的作用机制提供了新的见解,并将为开发下一代跨上皮递药系统提供信息。